Healthcare Industry News: non-small-cell lung cancer
News Release - January 18, 2010
Med BioGene Appoints World-Renowned Geneticist Dr. Michael R. Hayden as Director
VANCOUVER, BRITISH COLUMBIA - (HSMN NewsFeed) - Med BioGene Inc. (TSX-V:MBI ) is pleased to announce that Michael R. Hayden, MD, PhD, FRCPC, has joined the company's Board of Directors.Dr. Hayden is a Professor of Medical Genetics at the University of British Columbia (UBC), as well as the Director of the Center for Molecular Medicine and Therapeutics (CMMT) in Vancouver. The CMMT is a gene research center operating under UBC's Faculty of Medicine with approximately 170 research scientists, including faculty, graduate students and post-doctoral fellows. Dr. Hayden has also served as the Scientific Director of the Canadian Genetic Diseases Network since its inception in 1990.
Dr. Hayden focuses his research primarily on genetic diseases and predictive medicine and has authored over 600 peer-reviewed publications and invited submissions.
Dr. Hayden was a founder, director and Chief Medical Advisor of Aspreva Pharmaceuticals Corporation, a NASDAQ and Toronto Stock Exchange-listed company, which was acquired in 2007 by Galenica Group for US $915 million. He is also a director and Chief Scientific Officer of Xenon Pharmaceuticals Inc., a privately-held biotechnology company.
Dr. Hayden is the recipient of numerous prestigious awards and honors. He was awarded the Order of British Columbia in 2009; Canada's Health Researcher of the Year: Canadian Institutes of Health Research Michael Smith Prize in Biomedical and Clinical Research in 2008; the Prix Galien Canada (Research) award in 2007; the Award of Excellence of the Genetics Society of Canada and the Ottawa Life Sciences Award of Merit in 2001; the BC Biotechnology Alliance Award for Vision and Leadership in 2000; and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation in 1998. Furthermore, he was elected to the Royal Society of Canada in 1995, to the Board of the American Society of Human Genetics in 1994 and to the American Society of Clinical Investigation in 1992.
"Dr. Hayden is one of the world's preeminent experts in genetics and personalized medicine with a proven track-record of leadership and vision, both in the laboratory and commercially. He will bring to Med BioGene valuable experience and entrepreneurial vigor and we are very pleased to welcome him to our team," commented Erinn Broshko, Chief Executive Officer of MBI.
"I am delighted to be working with Med BioGene to advance personalized medicine and improve treatment options for patients diagnosed with non-small-cell lung cancer. Genomic-based technology in this area has shown the potential to make an impact on patient care by providing a greater understanding of each patient's cancer and it is important to advance research from the laboratory to commercial reality for the benefit of all patients," stated Dr. Hayden.
Dr. Hayden holds an MD and PhD from the University of Cape Town, completed a post-doctoral fellowship and further training at Harvard Medical School and is a Fellow of the Royal College of Physicians and Surgeons of Canada.
About Med BioGene
MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit www.medbiogene.com.
Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements include, but are not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Source: Med BioGene
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
